Agentic AI turns wasted windshield time into productive CRM updates and deploys always-on virtual reps to support providers ...
Gilead signs royalty-free licensing deals to broaden Ebola antiviral access, FDA approves Cosentyx for polymyalgia rheumatica ...
Secukinumab offers a new steroid-sparing option in polymyalgia rheumatica, a disease with frequent relapse and meaningful glucocorticoid-associated morbidity, particularly in older adults. Phase III ...
New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.
FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with primary membranous nephropathy (pMN) at risk ...
FDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, ...
Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.
Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from ...
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter ...
As Medicare negotiation, PBM reform, and cash-pay channels converge, winning on auditable net value matters more than cutting ...
Sustainable competitive advantage requires combining proprietary evidence, AI, and human expertise—not substituting one for ...
The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per ...